314 related articles for article (PubMed ID: 1674958)
1. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo.
Crossland KD; Lee VK; Chen W; Riddell SR; Greenberg PD; Cheever MA
J Immunol; 1991 Jun; 146(12):4414-20. PubMed ID: 1674958
[TBL] [Abstract][Full Text] [Related]
2. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
Yoshizawa H; Chang AE; Shu SY
Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
[TBL] [Abstract][Full Text] [Related]
3. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
4. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
5. Retroviral transduction of protein kinase C-gamma into tumor-specific T cells allows antigen-independent long-term growth in IL-2 with retention of functional specificity in vitro and ability to mediate tumor therapy in vivo.
Chen W; Schweins E; Chen X; Finn OJ; Cheever MA
J Immunol; 1994 Oct; 153(8):3630-8. PubMed ID: 7930583
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of murine T cell subsets with anti-CD3 antibody. Age-related defects in the expression of early activation molecules.
Ernst DN; Weigle WO; McQuitty DN; Rothermel AL; Hobbs MV
J Immunol; 1989 Mar; 142(5):1413-21. PubMed ID: 2521878
[TBL] [Abstract][Full Text] [Related]
8. Adoptively transferred antigen-specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2.
Chen W; Reese VA; Cheever MA
J Immunol; 1990 May; 144(10):3659-66. PubMed ID: 2332628
[TBL] [Abstract][Full Text] [Related]
9. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
[TBL] [Abstract][Full Text] [Related]
10. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction.
Hirsch R; Archibald J; Gress RE
J Immunol; 1991 Oct; 147(7):2088-93. PubMed ID: 1833451
[TBL] [Abstract][Full Text] [Related]
11. Immunoregulatory function of CD3+, CD4-, and CD8- T cells. Gamma delta T cell receptor-positive T cells from nude mice abrogate oral tolerance.
Fujihashi K; Kiyono H; Aicher WK; Green DR; Singh B; Eldridge JH; McGhee JR
J Immunol; 1989 Dec; 143(11):3415-22. PubMed ID: 2573632
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
Anderson PM; Blazar BR; Bach FH; Ochoa AC
J Immunol; 1989 Feb; 142(4):1383-94. PubMed ID: 2521662
[TBL] [Abstract][Full Text] [Related]
13. Regulatory function for murine intraepithelial lymphocytes. Two subsets of CD3+, T cell receptor-1+ intraepithelial lymphocyte T cells abrogate oral tolerance.
Fujihashi K; Taguchi T; McGhee JR; Eldridge JH; Bruce MG; Green DR; Singh B; Kiyono H
J Immunol; 1990 Oct; 145(7):2010-9. PubMed ID: 1975820
[TBL] [Abstract][Full Text] [Related]
14. T-deficient transmembrane signaling in CD4+ T cells of retroviral-induced immune-deficient mice.
Fitzpatrick EA; Bryson JS; Rhoads C; Kaplan AM; Cohen DA
J Immunol; 1992 Jun; 148(11):3377-84. PubMed ID: 1350288
[TBL] [Abstract][Full Text] [Related]
15. Concomitant administration of hapten and IL-2-toxin (DAB486-IL-2) results in specific deletion of antigen-activated T cell clones.
Bastos MG; Pankewycz O; Rubin-Kelley VE; Murphy JR; Strom TB
J Immunol; 1990 Dec; 145(11):3535-9. PubMed ID: 2147194
[TBL] [Abstract][Full Text] [Related]
16. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy.
Yoshizawa H; Sakai K; Chang AE; Shu SY
Cell Immunol; 1991 May; 134(2):473-9. PubMed ID: 1827049
[TBL] [Abstract][Full Text] [Related]
17. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
Thompson JA; Peace DJ; Klarnet JP; Kern DE; Greenberg PD; Cheever MA
J Immunol; 1986 Dec; 137(11):3675-80. PubMed ID: 3491145
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis.
Loeffler CM; Platt JL; Anderson PM; Katsanis E; Ochoa JB; Urba WJ; Longo DL; Leonard AS; Ochoa AC
Cancer Res; 1991 Apr; 51(8):2127-32. PubMed ID: 1826232
[TBL] [Abstract][Full Text] [Related]
19. T cell activation through TCR/-CD3 complex. IL-2 production of T cell clones stimulated with anti-CD3 without cross-linkage.
Tamura T; Nariuchi H
J Immunol; 1992 Apr; 148(8):2370-7. PubMed ID: 1532813
[TBL] [Abstract][Full Text] [Related]
20. Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma.
Eberlein TJ; Rosenstein M; Spiess PJ; Rosenberg SA
J Natl Cancer Inst; 1982 Jul; 69(1):109-16. PubMed ID: 6980314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
